Vorsetuzumab mafodotin
Humanized (from mouse) | |
Target | CD70 |
---|---|
Clinical data | |
Other names | SGN-75 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6476H10006N1726O2028S50(C49H78N6O11)3-5 |
Molar mass | 150 kg/mol |
Vorsetuzumab mafodotin (SGN-75) is an
cytotoxic agent.[citation needed
]
This drug was developed by
Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,[2] but development was discontinued in 2013.[3]
No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.[3]